Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT03865082 | Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206) | PHASE2 | ACTIVE NOT_RECRUITING | 30 | — | — | Oct 29, 2019 | Apr 1, 2022 | Feb 17, 2022 | 3 | United States |
Efficacy measure by objective response rate
Durability or response per RECIST v1.1
| Arm | Type | Description |
|---|---|---|
| IO Naive Subjects MSS CRC | EXPERIMENTAL | 8mg Tilsotolimod by intratumoral injection plus 3mg/kg Nivolumab (every three weeks for four doses followed by 480mg dose every four weeks) and 1mg/kg Ipilimumab every three weeks for four doses intravenous |
| Name | Type | Description |
|---|---|---|
| Tilsotolimod | DRUG | 9 doses of Tilsotolimod Intratumoral injection administered as a dose of 8mg at Week 0 Day 1 (7 days prior to the start of Cycle 1), Day 1 and Day 8 of Cycle 1, and on Day 1 of Cycles 2 through 7. |
| Nivolumab | DRUG | Specified dose on specified days. |
| Ipilimumab | DRUG | Specified dose on specified days. |
Main Inclusion Criteria: 1. Subject must be willing and able to sign the informed consent and comply with study protocol. 2. Must be ≥ 18 years of age (males and females). 3. ≥ 1 lesion accessible for i.t. injection and biopsy(ies). 4. Eastern Cooperative Oncology Group (ECOG) performance status of...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab, V503, GARDASIL |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| AstraZeneca PLC | AZN | 1 | — | Trastuzumab deruxtecan |